C alprotectin is a calcium-binding protein that accounts for approximately 60% of the cytosolic protein in neutrophils and has antimicrobial and antiproliferative properties. 1 Because calprotectin is stable in feces, it can be used as a marker for neutrophil infiltration into gastrointestinal tissues and therefore of gut inflammation. 1 Gut inflammation in inflammatory bowel disease (IBD) is typically assessed by endoscopy, so measuring the fecal concentration of inflammatory markers such as calprotectin has been proposed as a noninvasive method to assist in the diagnosis and assessment of disease severity and response to therapy. 1 In most patients with IBD, fecal calprotectin (FC) levels normalize in parallel with mucosal healing. 2 In ulcerative colitis (UC), the FC level correlates positively with symptom scores and endoscopic disease activity.
3-6 D'Haens et al 4 reported that an FC level .250 mg/kg predicts active mucosal disease with a sensitivity of 71% and a specificity of 100%. García-Sánchez et al 7 also reported that a baseline FC level .120 mg/kg was associated with a 6-fold increase in likelihood of disease activity outbreak in patients with UC in clinical remission, and D'Incà et al 8 that a baseline FC level .130 mg/kg was the best cutoff for predicting relapse within 1 year, with a sensitivity of 68% and specificity of 68%. A recent meta-analysis of prospective studies found that baseline FC levels predicted relapse in quiescent UC with a pooled sensitivity of 77% (95% confidence interval [CI] , 67-85) and specificity of 71% (95% CI, 64-77). 9 Few studies have examined the changes in FC levels during treatment. We recently reported that the anti-tumor necrosis factor a agent infliximab decreased FC levels in 42 of 53 patients with UC (80%) within 10 weeks, with decreases already observed within 2 weeks. 10 This suggested that FC levels measured during treatment can be used to assess treatment response. In support of this, Molander et al 11 recently reported that in patients with IBD treated with anti-tumor necrosis factor a agents, an FC level .139 mg/kg at the end of the induction phase predicted clinically active IBD after 1 year with a sensitivity of 72% and a specificity of 80%. In this study, we wanted to explore the value of routine calprotectin measurements in patients with UC receiving infliximab maintenance therapy.
MATERIALS AND METHODS

Overall Study Design
This 1-year prospective multicenter open-label longitudinal study was conducted at 17 centers in Belgium and 7 in Norway between March 18, 2008 , and December 14, 2010. The main objective of the study was to determine whether FC levels can potentially be used in clinical practice to monitor and/or predict disease activity in patients with UC under infliximab maintenance therapy. The study was conducted in compliance with the International Committee for Harmonisation Guideline for Good Clinical Practice and the Helsinki Declaration and was approved by the institutional review board at each site. Written informed consent was obtained from all included patients.
Patients
Adult patients ($18 years) with UC responding to infliximab induction therapy (5 mg/kg at initiation and 2 and 6 weeks later 12 ) defined as a decrease in Mayo score $3, along with a Mayo bleeding subscore #1 and a Mayo endoscopic subscore #1, or adult patients with UC in clinical remission under infliximab maintenance therapy (at least 4 infusions 5 mg/kg every 8 weeks) were enrolled. Exclusion criteria included cyclosporine treatment in the last month before inclusion, change in immunomodulator dose in the last 4 weeks, evidence of active infection, active tuberculosis, heart failure NYHA class 3-4, colon cancer or dysplasia, and severe or unstable hepatic, gastrointestinal, cardiovascular, respiratory, neurological, psychiatric, hematological, or renal disease. Target enrollment was 100 patients based on a report from Tibble et al 13 that approximately 100 patients in remission at inclusion is sufficient to evaluate the value of FC for predicting relapse in patients with IBD.
Treatments
During the study, all patients received infliximab maintenance therapy at 5 mg/kg with 8-week intervals. Patients continued in the study for 52 weeks or until they relapsed (see below).
Patients were removed from the study if they had adverse events or conditions that required discontinuation of infliximab treatment. Changes in concomitant therapies were allowed according to daily practice. Non-steroidal anti-inflammatory drug treatment was allowed during treatment (a sensitivity analysis showed no effect of non-steroidal anti-inflammatory drug use on the presented sensitivities and specificities of calprotectin measurement to model flare or remission).
Assessments
During the study, patients provided a stool sample (1 g) every 4 weeks. At inclusion and at week 52, stool samples were collected immediately before the start of bowel cleansing for the scheduled endoscopy. All samples were frozen at 2208C within 48 hours. FC levels were measured using a PhiCal enzyme-linked immunoassay kit (Scimedx, Denville, NJ) as described previously. 10 Sigmoidoscopies were performed at enrollment and at study end (week 52 for all patients except those who required a change in treatment due to relapse) by physicians, who scored the results according to the Mayo endoscopic subscore (0, normal; 1, mild; 2, moderate; 3, severe).
14 At each infusion of infliximab (weeks 0, 8, 16, 24, 32, 40, and 48) or at relapse, physicians calculated a partial Mayo score, which was the sum of Mayo subscores for stool frequency, amount of blood in the stool, and the physician's global assessment. Blood C-reactive protein concentration, erythrocyte sedimentation rate, serum albumin concentration, blood hemoglobin concentration, and platelet count were measured at each infusion or flare by standard clinical laboratory methods.
Definitions and Classification of Treatment Response
Patients were considered to be in sustained deep remission if they had an endoscopic Mayo subscore ¼ 0 at inclusion and at week 52, as well as a partial Mayo score ,3 at all times. A relapse was defined as insufficient control of UC, necessitating a change in treatment or an incomplete mucosal healing defined as an endoscopic Mayo subscore $2 at week 52. Because our goal was to assess the value of fecal calprotectin in daily clinical practice, the definition of "insufficient control" was not preset but remained fully in the discretion of the treating physician. The treatment responses for the remainder of the patients were subdivided into two subgroups: sustained clinical remission (partial Mayo score ,3 at all times but an endoscopic score of 1 at week 52) and clinical flare (partial Mayo score $3 at any time that did not necessitate a change in treatment).
Statistical Analyses
All analyses were performed using SPSS version 18 (Armonk, NY). Graphs were generated using Excel version 14.0.6123.5001 (Microsoft, Redmond, WA). Statistical analysis was performed for patients who completed the study according to the protocol, whose treatment response could be determined (i.e., sigmoidoscopy results at enrollment and study end), and who had valid FC data. General estimation equations after log transformation were used to determine mean FC values over the 12 months of the study. Because FC levels were not normally distributed, median FC levels and interquartile (IQ) ranges were calculated at individual time points. Wilcoxon's signed-rank test was used to compare paired data. Proportions were compared using Fisher's exact test or the x 2 test. Differences in paired data and proportions were considered significant at P , 0.05. Hazard ratios were determined by Cox regression to evaluate the risk of relapse over time and were considered statistically significant when the lower limit of the 95% CI was .1.0. Correlations between dichotomous outcome variables and continuous variables (FC level, C-reactive protein concentration, erythrocyte sedimentation rate, serum albumin concentration, blood hemoglobin concentration, and platelet count) were assessed by calculating the area under the curve (AUC) of receiver operator curves (ROCs) as described by Hanley et al. 15 
RESULTS
Patients
A total of 113 patients were included (83 in Belgium, 30 in Norway). Characteristics of the study population are found in Table 1 .
Of the 113 patients included in the study, 5 discontinued before week 52 due to adverse events, including 2 for hypersensitivity reactions, 1 for arthralgia, 1 for an adrenal tumor, and 1 for polyneuropathy. Two female patients discontinued before week 52 due to voluntary withdrawal unrelated to an adverse event. These 7 patients were not included in the statistical analyses because they lacked final sigmoidoscopy results and, therefore, their treatment response could not be classified. An additional 19 patients were excluded from the statistical analyses because they had insufficient stool samples (n ¼ 16) or had missing sigmoidoscopy results at week 52 (n ¼ 3). Thus, 87 patients were included in the analysis set.
Treatment Response
Of the 87 patients in the analysis set, 30 (34.5%) were considered to have been in sustained deep remission throughout the study and 13 (14.9%) were considered to have relapsed (Fig. 1) . The remainder of the patients were split into two subgroups: those who were in sustained clinical remission but with an endoscopic Mayo score of 1 at week 52 (n ¼ 28; 32.2%) and those who had experienced clinical symptoms not requiring a change in treatment (n ¼ 16; 18.4%).
Mean FC Levels in the Different Groups (Calculated by Generalized Estimating Equation Modeling)
In patients who were considered to have been in sustained deep remission, the mean FC level over the 12 months of the study was 27 mg/kg (95% CI, 21-36 mg/kg). In these patients, the median FC level remained below 40 mg/kg at all times (Fig. 2) . The FC level in these patients was significantly lower than in the patients whose disease relapsed, whose mean FC level was 125 mg/kg (95% CI, 64-243 mg/kg; P , 0.001). The mean FC levels were also significantly higher in subgroup of patients experiencing clinical flares than in patients in sustained clinical remission (61 mg/kg [95% CI, 65-244 mg/kg] versus 33 mg/kg [95% CI, 25-42 mg/kg]; P , 0.001).
FC Levels at the Moment of Relapse
In patients whose disease relapsed, FC levels were significantly higher at the moment of relapse than at baseline (median, 477 [IQ range, 74-677] mg/kg versus 58 [IQ range, 15-677] mg/kg; P , 0.001). FC levels were elevated as early as 3 months before the relapse (Fig. 3) .
Predictive Value of the Baseline FC Measurement
Sustained deep remission was slightly but not significantly more frequent in patients with baseline FC levels ,50 mg/kg than in patients whose FC levels were .50 mg/kg (23/59 [39.0%] versus 7/28 [25.0%]; P ¼ 0.2), but it was significantly more frequent in patients with a baseline FC level ,150 mg/kg than in patients above this cutoff (28/71 [39.4%] versus 2/16 [12.5%]; P ¼ 0.046). Despite this, the hazard for relapse was not significantly higher in patients with baseline FC levels .150 mg/kg (hazard ratio, 2.4; 95% CI, 0.7-8.0). Also, baseline FC levels in 
Discrimination of Relapse and Deep
Remission by Single FC Level Measured at the Last Evaluation ROC analysis using the FC level at the moment of relapse or last analysis gave a mean AUC 6 standard error of 0.85 6 0.07 to discern relapse and sustained deep remission. This analysis indicated that a cutoff of .300 mg/kg FC could predict relapse with 93.3% specificity and 58.3% sensitivity, whereas a cutoff of ,50 mg/kg FC could predict sustained deep remission with 83.3% specificity and 83.3% sensitivity. At the moment of flare, 2 out of 13 (15%) patients had a calprotectin score ,50.
Predictive Value of a Single FC Level Measured during the 12-Month Study
Although the cutoffs of 50 and 300 mg/kg at last evaluation could discriminate relapse and deep remission, a single FC value from the serial measurements had limited predictive value: Of the 30 patients in sustained deep remission, 23 (76.7%) had at least 1 FC measurement .50 mg/kg, and 8 (26.7%) had at least 1 measurement .300 mg/kg. Thus, the specificity to predict the absence of sustained deep remission was only 23.3% (95% CI, 14.3%-32.1%) using a cutoff of .50 mg/kg FC and 73.3% (95% CI, 64%-92.6%) using a cutoff of .300 mg/kg.
Predictive Value of 2 Consecutive FC Measurements
Two consecutive FC levels .300 mg/kg could predict relapse with 61.5% (95% CI, 51.3%-71.7%) sensitivity and 100% specificity ( Table 2 ). To confirm the sensitivity of the analysis, it was used to compare clinical flare and sustained clinical remission. Two consecutive FC levels .300 mg/kg could discriminate clinical flare from sustained clinical remission with a sensitivity of 43.8% (95% CI, 33.4%-54.2%) and a specificity of 89.3% (95% CI, 92.8%-95.8%).
Prediction of Treatment Response Using Blood Markers Measured during Infliximab Maintenance Treatment
According to ROC analysis, the FC level at the moment of relapse was significantly better than the blood C-reactive protein concentration at predicting relapse (AUC, 0.85 6 0.07 versus 0.58 6 0.11; P ¼ 0.015). In addition, the AUC for predicting relapse was not significantly higher for single erythrocyte sedimentation rate, serum albumin concentration, blood hemoglobin concentration, or platelet counts alone or combined with FC (data not shown).
DISCUSSION
This prospective study measured FC levels every 4 weeks over 1 year in patients with UC receiving maintenance treatment with infliximab. The study showed that FC levels are persistently low in patients in deep clinical and endoscopic remission (sustained deep remission) and that the 2 consecutively elevated FC levels are predictive of disease recurrence.
The definition of remission in UC is still a matter of debate. Remission is usually defined as mucosal healing, but this can be defined as an endoscopic Mayo score of 0 or #1. 16 In this study, approximately one-third of the patients (34%) were in deep remission at all times according to the most stringent criterion, namely, Previous studies have demonstrated a correlation between FC and the severity of colorectal inflammation, especially in UC, and a few have examined the potential of FC measurements to predict relapse. 1 Tibble et al 13 reported that baseline FC concentrations .250 mg/kg (50 mg/L by the old method) were associated with a 13-fold increase in the risk of relapse within 12 months. Similarly, Costa et al 17 reported that a baseline FC level .150 mg/kg was associated with a 14-fold increase in risk of relapse in UC and was the most sensitive (89%) and specific (82%) predictor of eventual relapse, with only 19% of patients with FC levels above this threshold still in remission after 1 year. Using this same cutoff, Gisbert et al 18 reported 69% sensitivity and 69% specificity for predicting relapse in IBD. However, in their study, only 30% of IBD patients with FC levels .150 mg/kg relapsed, and the sensitivity was only 31% (91% specificity) for predicting relapse in UC. Molander et al, 11 in contrast, reported that in patients with IBD treated with anti-tumor necrosis factor a therapy, 139 mg/kg was the best cutoff for predicting relapse (sensitivity of 72% and specificity of 80%).
In contrast to these studies, we were not able to predict relapse based on the baseline FC levels. Although patients whose disease flared had a nonsignificant trend toward higher FC levels, an increased baseline level could not be used to predict flare during the 1-year follow-up. Our inability to predict relapse using baseline FC levels was likely due the fact that most patients were in profound remission at the start of the study and were already on maintenance therapy. This resulted in low FC levels and a low frequency of relapse (16%). In the other studies, patients received a variety of nonbiological therapies, and the risk of flare ranged from 16% to as high as 70%. 11, 13, 17, 18 Differences in the sensitivities of the FC detection assays might have also resulted in different findings. 19 Our results suggest that rather than baseline levels, FC levels measured during treatment are the best for predicting recurrence of active disease. A loss of response to infliximab during maintenance therapy corresponded with a significant increase in FC levels as much as 3 months before the appearance of clinical symptoms. In a previous study of patients with UC, we also found that infliximab induced significant changes in FC levels within 2 weeks and that after 10 weeks, it decreased FC levels to ,50 mg/kg in 58% of the patients, corresponding to an at least 80% decrease from baseline. 10 A close temporal relationship between FC levels and clinical response has also been observed in Crohn's disease. 20 Although the cutoffs of 50 and 300 mg/kg at last evaluation could discriminate relapse and deep remission, a single FC value from the serial measurements had limited predictive value: nearly 80% of the patients in sustained deep remission had at least 1 FC measurement .50 mg/kg. However, two consecutive FC levels .300 mg/kg collected 2 months apart predicted relapse with 100% specificity. Two consecutive FC levels .300 mg/kg collected 2 months apart also differentiated clinical flare from sustained clinical remission with 89.3% specificity, supporting the robustness of this approach. Repeated measures of FC might therefore help adjust therapy for patients with UC before the appearance of clinical symptoms. Further studies are needed to determine whether reducing the interval for measuring FC levels can improve the sensitivity to predict loss of treatment response. Whether these FC measurements should be used alone or in combination with partial clinical Mayo scores also warrants further investigation.
A single FC level at the moment of relapse was better associated with active disease than the blood C-reactive protein concentration. Other blood markers, including the erythrocyte sedimentation rate, serum albumin, hemoglobin, and platelet counts alone or in combination with FC, did not improve the ability to predict flare. This agrees with others' findings that blood markers are less useful than fecal markers for predicting disease recurrence. 21, 22 In conclusion, this study is the first to show that routine serial measurements of fecal calprotectin could be of value in disease monitoring in patients with UC receiving infliximab maintenance therapy. Sustained low FC levels predict sustained deep remission and a low risk for relapse. On the contrary, relapse is preceded by an increase in FC level at least 3 months before the appearance of symptoms. Two consecutive elevated FC measurements are better than 1 at predicting disease flares in UC.
